Macular Degeneration Treatment Market is forecast to reach a value of US$ 13,195.7 Mn by 2028 at a CAGR of 7.0% between 2022 and 2028 | Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc.

Age-related damage to the macula results in macular degeneration, an eye condition that can cause central vision to become blurry. Although there is no cure for macular degeneration (AMD), medication can halt the condition and prevent catastrophic visual loss. The stage and kind determine the treatment, though. Since AMD is now untreatable, the doctor will likely just monitor the patient’s eyes through routine eye exams. Macular degeneration cannot be reversed, although certain therapies can slow or stop its progression. There is currently no cure for dry AMD. But there are many clinical studies running right now.

Click Here for Sample Copy (Use corporate email ID Get Higher Priority) @ https://www.coherentmarketinsights.com/insight/request-sample/5149

Market Statistics

By the end of 2022, the market for macular degeneration treatments is expected to be worth US$8,780.6 Mn.

Drivers

The worldwide market for macular degeneration treatments is expected to grow at a faster than average during the projected period due to rising public awareness of macular degeneration and its treatment. For instance, AMD is a significant contributor to permanent blindness, hence raising awareness of AMD is crucial to preventing blindness. The National Eye Health Education Program (NEHEP) was developed by the National Eye Institute (NEI) to assist community and health professionals in raising awareness of eye health. Additionally, in February 2020, Bausch Health partnered with the nonprofit group Prevent Blindness to run social media ads to educate people about macular degeneration.

Opportunities

Due to the increased incidence of retinal diseases globally, there is a growing focus on the development of macular degeneration treatments, which is anticipated to present participants in the global macular degeneration treatment market with considerable potential prospects. Market competitors are concentrating on releasing innovative therapies since there is an increased need for safe and effective therapy. For instance, Sam Chun Dang Pharm Co. Ltd. began a phase III clinical research in August 2020 to evaluate the immunoresponse, safety, tolerance, efficacy, and efficacy of SCD411 in patients with wet AMD. In April 2022, the trial’s conclusion was anticipated.

Restraints

Major challenges that are anticipated to restrain market growth for macular degeneration treatments worldwide include rising off-label medication use and a lack of knowledge about macular degeneration. In adults 60 and older, AMD is the most common cause of permanent vision loss. It’s crucial to be aware of AMD and its symptoms for this reason. However, by the time AMD symptoms manifest, as with many age-related eye disorders, it is too late to reverse any vision loss. Therefore, individuals should be aware of AMD (particularly the elderly).

For More Information or Query or Customization before Buying, Visit @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5149

Impact

The COVID-19 outbreak has had a disagreeable effect on the market. Hospital and clinical visits were dramatically decreased as a result of public transportation restrictions, increased infection risk, and other factors. Age-related macular degeneration (AMD) patients who contract SARS-CoV-2 are more likely to experience severe complications, including the need for oxygen support and death, according to a research study published in August 2020 in Nature Medicine.

Key Takeaways

The market for treatments for macular degeneration was estimated to be worth 8,208.7 million in 2021 and is anticipated to grow at a 7.0% CAGR from 2022 to 2028 to reach US$ 13,195.7 million.

Wet age-related macular degeneration held a dominant position in the global market for macular degeneration treatments in 2021, accounting for 93.9% of the market’s value. Increasing approval and the introduction of new products are anticipated to fuel the segment’s growth over the course of the forecast period.

Market Trends

The world’s ageing population is anticipated to fuel the expansion of the macular degeneration treatment industry. Age makes people more susceptible to AMD. AMD is more common in those who are 60 years of age and older. The WHO predicts that by 2030, one in every six people worldwide will be 60 or older, and by 2050, the number of individuals worldwide who are 60 or older will double.

Competitive Landscape

Bausch Health Companies Inc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., REGENXBIO Inc., Regeneron Pharmaceutical Inc., Aerie Pharmaceutical Inc., and Panoptica, are some of the major companies competing in the worldwide macular degeneration therapy market.

Recent Developments

Pfizer launched an exploratory trial for Macugen in March 2020 on individuals with nAMD (neurovascular age-related macular degeneration) to ascertain the advantages and effectiveness of protecting these patients’ eyesight.

Beova was given FDA approval by Novartis in October 2019. In the case of individuals with wet AMD, it assisted in lowering fluid intake.

Avail Discount on various license types on Immediate Purchase @ https://www.coherentmarketinsights.com/insight/buy-now/5149

Table of Contents:

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Type
     • Market Snapshot, By Stage od Disease
     • Market Snapshot, By By Route of Administration
     • Market Snapshot, By Sales Channel
     • Market Snapshot, By Geography
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Increasing burden of retinal disorders worldwide
     • Lack of awareness regarding macular degeneration
     • Increasing demand for safe and effective treatment
   • Impact Analysis
   • Key Highlights
   • Regulatory Scenario
   • Product launch/Approvals
   • PEST Analysis
   • PORTER’s Analysis
   • Merger and Acquisition Scenario
4. Macular Degeneration Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
   • COVID-19 Epidemiology
   • Supply Side and Demand Side Analysis
   • Economic Impact
5. Macular Degeneration Treatment Market, By Type, 2017-2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Dry Age-related Macular Degeneration
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Wet Age-related Macular Degeneration
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
6. Macular Degeneration Treatment Market, By Stage of Disease, 2017-2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Early-stage AMD
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Intermediate AMD
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Late-stage AMD
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
7. Macular Degeneration Treatment Market, By Route of Administration, 2017-2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Intravenous Route
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Intravitreal Route
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
8. Macular Degeneration Treatment Market, By Sales Channel, 2017-2028, (US$ Mn)
   • Introduction
     • Market Share Analysis, 2022 and 2028 (%)
     • Y-o-Y Growth Analysis, 2017 – 2028
     • Segment Trends
   • Ambulatory Surgical Centres
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Hospitals
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
   • Other Sales Channels
     • Introduction
     • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)